1. Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. Issue 2 (28th January 2021) Authors: Bhurani, Mansi; Admojo, Lorenz; Van Der Weyden, Carrie; Twigger, Robert; Bazargan, Ali; Quach, Hang; Zimet, Allan; Coyle, Luke; Lindsay, Julian; Radeski, Dejan; Hawkes, Eliza; Kennedy, Glen; Irving, Ian; Gutta, Naadir; Trotman, Judith; Yeung, James; Dunlop, Lindsay; Hua, Minh; Giri, Pratyush; Yue... Journal: Leukemia & lymphoma Issue: Volume 62:Issue 2(2021) Page Start: 330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Issue 10168 (19th January 2019) Authors: Horwitz, Steven; O'Connor, Owen A; Pro, Barbara; Illidge, Tim; Fanale, Michelle; Advani, Ranjana; Bartlett, Nancy L; Christensen, Jacob Haaber; Morschhauser, Franck; Domingo-Domenech, Eva; Rossi, Giuseppe; Kim, Won Seog; Feldman, Tatyana; Lennard, Anne; Belada, David; Illés, Árpád; Tobinai, Kense... Journal: Lancet Issue: Volume 393:Issue 10168(2019) Page Start: 229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. Issue 3 (17th January 2023) Authors: Lasater, Elisabeth A.; Amin, Dhara N.; Bannerji, Rajat; Mali, Raghuveer Singh; Barrett, Kathy; Rys, Ryan N.; Oeh, Jason; Lin, Eva; Sterne‐Weiler, Tim; Ingalla, Ellen Rei; Go, MaryAnn; Yu, Shang‐Fan; Krem, Maxwell M.; Arthur, Chris; Hahn, Uwe; Johnston, Anna; Karur, Vinit; Khan, Nadia; Marlton, Pa... Journal: American journal of hematology Issue: Volume 98:Issue 3(2023) Page Start: 449 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗